Benzingaยท2025-09-18 19:46Core Insights - Nanobiotix SA announced new results from an ongoing Phase 1 study evaluating JNJ-1900 (NBTXR3) in combination with immune checkpoint inhibitors for advanced cancer patients, specifically focusing on primary cutaneous melanoma [1][4] - The study involved 21 patients who had previously shown resistance to anti-PD-1 treatments, and the combination therapy demonstrated a favorable safety profile [1] - The stock price of Nanobiotix (NBTX) increased by 22.03%, reaching $12.45 [4] Patient Outcomes - A total of 16 patients experienced treatment-emergent adverse events (TEAEs) of grade 1, grade 2, or grade 3+ related to the overall therapeutic regimen [2] - Among 19 evaluable patients, the best observed objective response rate (ORR) was 47.4%, with four complete responses and five partial responses [5] - The disease control rate (DCR) across all lesions was 78.9%, and a DCR of 100% was observed in tumors that were injected and irradiated [5] - The median overall survival (mOS) for all treated patients was 14.6 months [5] Immune Response Insights - A relationship was noted between the depth of local response and systemic tumor regression, indicating potential priming or reactivation of the immune response [4]